Display options
Cite
Kumar K, Kwaku KF, Verrier RL. Treatment options for patients with coronary artery disease identified as high risk by T-wave alternans testing. Curr Treat Options Cardiovasc Med. 2008;10(1):39-48doi: 10.1007/s11936-008-0005-1.
Kumar, K., Kwaku, K. F., & Verrier, R. L. (2008). Treatment options for patients with coronary artery disease identified as high risk by T-wave alternans testing. Current treatment options in cardiovascular medicine, 10(1), 39-48. https://doi.org/10.1007/s11936-008-0005-1
Kumar, Kapil, et al. "Treatment options for patients with coronary artery disease identified as high risk by T-wave alternans testing." Current treatment options in cardiovascular medicine vol. 10,1 (2008): 39-48. doi: https://doi.org/10.1007/s11936-008-0005-1
Kumar K, Kwaku KF, Verrier RL. Treatment options for patients with coronary artery disease identified as high risk by T-wave alternans testing. Curr Treat Options Cardiovasc Med. 2008 Feb;10(1):39-48. doi: 10.1007/s11936-008-0005-1. PMID: 18325306.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Cardiovasc Med. 2008 Feb;10(1):39-48. doi: 10.1007/s11936-008-0005-1.

Treatment options for patients with coronary artery disease identified as high risk by T-wave alternans testing.

Current treatment options in cardiovascular medicine

Kapil Kumar, Kevin F Kwaku, Richard L Verrier

Affiliations

  1. Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Room 223, Boston, MA 02115, USA.

PMID: 18325306 DOI: 10.1007/s11936-008-0005-1

Abstract

Risk stratification for primary prevention of sudden cardiac death (SCD) remains a major challenge in cardiology. The utility of T-wave alternans (TWA) as a marker of risk of life-threatening ventricular tachycardia and fibrillation is supported by two decades of basic and clinical research. Both frequency- and time-domain methods have been developed, validated, and made available in clinical practice. A principal application of TWA testing has been to improve assessment of patients with depressed left ventricular ejection fraction (EF;

References

  1. J Cardiovasc Electrophysiol. 2003 Sep;14(9 Suppl):S87-95 - PubMed
  2. J Cardiovasc Electrophysiol. 2005 Jun;16(6):625-8 - PubMed
  3. J Cardiovasc Electrophysiol. 2003 Jul;14(7):705-11 - PubMed
  4. N Engl J Med. 2003 Apr 3;348(14):1309-21 - PubMed
  5. Circulation. 2004 Sep 14;110(11):1413-7 - PubMed
  6. Ann Noninvasive Electrocardiol. 2005 Jan;10(1):110-20 - PubMed
  7. J Am Coll Cardiol. 1999 Mar;33(3):598-604 - PubMed
  8. J Am Coll Cardiol. 2009 Mar 31;53(13):1130-7 - PubMed
  9. Lancet. 1999 Apr 24;353(9162):1390-6 - PubMed
  10. Lancet. 1994 Nov 19;344(8934):1383-9 - PubMed
  11. Lancet. 1997 Mar 8;349(9053):675-82 - PubMed
  12. J Am Coll Cardiol. 1991 Sep;18(3):687-97 - PubMed
  13. N Engl J Med. 1999 Sep 2;341(10):709-17 - PubMed
  14. J Am Coll Cardiol. 2006 Feb 21;47(4):769-73 - PubMed
  15. J Am Coll Cardiol. 2006 Sep 19;48(6):1228-33 - PubMed
  16. J Cardiovasc Electrophysiol. 2005 Jun;16(6):620-4 - PubMed

Publication Types